DRUG
desmopressin tablet
Administration of desmopressine tablet
Status
Completed
Phase
Phase 4
Enrollment
24
Locations
1
Results
Not posted
Publications
0
Study summary
Alarm-treatment as well as Desmopressin, a synthetic analogue of human vasopressin, are considered the only evidence-based medicine (EBM) IA treatments in monosymptomatic nocturnal enuresis (MNE). Desmopressin exists in three different formulations for ambulant use: nasal spray, tablet and lyophilisate (MELT) each with differences in bioavailability (spray 2%, tablet 0.2%, MELT 0.5%). There 's insufficient evidence to confirm the actually used bioequivalent doses ( 10µg spray = 120µg MELT= 0.2mg tablet). Although so frequently used, very few pharmacokinetic and -dynamic data on desmopressin are available for children. Due to prolonged half life, associated with waterintoxication,the nasal spray has a black box warning from the FDA and is no longer recommended . For some authors oral formulations appear to be a safer alternative. However, based on clinical experience of less response rate with oral formulations, lower biodisponibility is suspected. Adult research confirms low bioavailability of tablets but also show major influences by food-intake and changes in gastro-intestinal motility. To achieve maximum efficacy, recommendations are to take desmopressin tablet 1 hour before bedtime and 2 hours after meal: this is unrealistic in schoolaged children since there never is 3 hours between evening meal and bedtime. In 2005 a dose response study demonstrated superior pharmaco-kinetic and dynamic properties for desmopressin Lyophilisate MELT formula. Since these results implicate superior action of MELT, often a change to MELT is recommended if there is a suboptimal response with tablet: sublingual absorption would eliminate the influence of food-intake. However, for this statement there's no evidence, since these tests were all conducted in children in fasting condition. Only one clinical study demonstrates bioequivalence for MELT and tablet. Hypothesis is that desmopressin MELT formulation has a better bioavailability when administered together with meal due to its sublingual absorption.
Interventions
DRUG
Administration of desmopressine tablet
DRUG
Administration of desmopressine MELT formulation
Timeline
First posted
Dec 21, 2009
Study start
Dec 2009
Primary completion
Apr 2010
Study completion
Apr 2010
Results posted
Not reported
Registry updated
Feb 6, 2019
Outcomes
Bioavailability of desmopressine MELT and tablet when taken with meal.
Time frame · at 1h, 2h and 6h post adminstration
Pharmacokinetic and pharmacodynamic for desmopressine MELT and tablet.
Time frame · at 1h, 2h, 3h, 6h and 8h post administration
Eligibility
Inclusion Criteria: * children aged 6-16 years old * with MNE and nocturnal polyuria * treated with desmopressin tablet, non or partial responders, for whom change to MELT formulation is indicated according to the international standard guidelines. Exclusion Criteria: * history of urologic disease, diurnal urinary incontinence, diabetes insipidus, urinary tract infection, clinically significant disease * No systemic use of antibiotics, diuretics, other medication that influences urinary concentrating mechanism * abnormalities of oral mucosa which could influence drugrelease or absorption
Study locations
Belgium. Showing up to 24 locations stored in the fast local snapshot.
University Hospital Ghent
Ghent, Belgium
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Zhaoyun Zhang · Craniopharyngiomas · Pituitary Macroadenoma
Phase 4
Enrolling by invitation
152
2026-07
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Cushing Syndrome
Phase 2
Recruiting
140
2026-07
Hamilton Health Sciences Corporation · Chronic Kidney Diseases · Acute Kidney Injury
Phase 3
Recruiting
100
2026-05
Rochester General Hospital · Hyponatremia Symptomatic · Osmotic Demyelination Syndrome
Not applicable
Enrolling by invitation
800
2026-05
National Institute of Neurological Disorders and Stroke (NINDS) · Cushing's Disease · Pituitary Adenoma
Not applicable
Recruiting
22
2026-04
Ain Shams University · Nocturnal Enuresis · Vitamin D Deficiency
Not applicable
Completed
90
2026-03
Menoufia University · Nocturnal Enuresis in Children · Desmopressin
Not applicable
Completed
398
2026-01
Ferring Pharmaceuticals · Adverse Drug Event
Not applicable
Completed
1,099,551
2025-12
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.